What is the Current Share Price of Shalby Ltd?
- Answer Field
-
Shalby Ltd share price is for NSE ₹ 222.22 & for BSE ₹ 222.45 as on Nov 20 2025 03:30 PM.
Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply
As of the latest trading session, SHALBY LIMITED share price is currently at ₹ 222.22, which is up by ₹ 1.29 from its previous closing. Today, the stock has fluctuated between ₹ 215.01 and ₹ 225.99. Over the past year, SHALBY LIMITED has achieved a return of 3.26 %. In the last month alone, the return has been -10.62 %. Read More...
| Particulars | SEP 2025 (Values in Cr) |
|---|---|
| Revenue | 223.97 |
| Operating Expense | 199.21 |
| Net Profit | 19.75 |
| Net Profit Margin (%) | 8.81 |
| Earnings Per Share (EPS) | 1.84 |
| EBITDA | 44.77 |
| Effective Tax Rate (%) | 35.37 |
| Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
|---|---|---|---|---|---|
| APOLLO HOSPITALS ENTER. L | 7457.95 | 64.14 | 11.80 | 107233.88 | 6002.15 / 8099.00 |
| FORTIS MALAR HOSPITALS LIMITED | 64.77 | 26.76 | 3.53 | 121.39 | 52.31 / 98.70 |
| SHREE PACETRONIX LTD. | 263.20 | 44.24 | 5.64 | 102.65 | 61.11 / 283.15 |
| TRANSGENE BIOTEK LTD. | 3.65 | 0.00 | 3.00 | 27.66 | 3.21 / 8.00 |
| Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
|---|---|---|---|---|---|
| APOLLO HOSPITALS ENTER. L | 7457.95 | 76.50 | 11.51 | 107233.88 | 6002.15 / 8099.00 |
| Surlux Diagnostic Ltd | 1.40 | 0.84 | 0.13 | 0.49 | 0.00 / 0.00 |
| CHENNAI MEENAKSHI MULTISPECIAL | 45.60 | 0.00 | -13.25 | 34.06 | 28.34 / 59.90 |
| KOVAI MEDICAL CENTER & HOSPITA | 5970.75 | 28.58 | 5.48 | 6532.00 | 4810.20 / 6725.00 |
Choose a Plan That Suits Your Goals and Needs
For Q1 of FY 25-26, the company's consolidated sales were ₹296.43 crore, and its net profit for the period stood at ₹7.68 crore. In the corresponding Q1 of FY 24-25, the sales were ₹278.89 crore with a net profit of ₹14.74 crore for the period.
Date Source: screener.in, and corporate filings on NSE/BSE
For FY 24-25, the company reported consolidated sales of ₹1,087 crore and a net profit of ₹2 crore. In the preceding year, FY 23-24, the company's sales were ₹934 crore, and the net profit was ₹84 crore.
Date Source: screener.in, and corporate filings on NSE/BSE
The company's stock has a face value of ₹10.00 per share and pays a dividend yield of 0.52%. The company has not yet declared any dividend for the current financial year, while it had announced a dividend for FY 2024-25 of ₹1.20 per share with ex-date of 19 September, 2024.
Date Source: screener.in, and corporate filings on NSE/BSE
Shalby Limited was originally incorporated as a private limited company in Ahmedabad on August 30, 2004, under the name 'Shalby Hospital Private Limited'. Over the following years, the company's corporate structure and name evolved to reflect its growth. In 2006, it was converted into a public limited company, and its name was changed first to 'Shalby Hospital Public Limited' and then to 'Shalby Hospitals Limited'. The company adopted its current name, Shalby Limited, in February 2008. The company operates a chain of multi-speciality hospitals headquartered in Ahmedabad, providing a range of medical and surgical services.
The hospitals in the Shalby network are primarily tertiary care facilities, with some units also offering quaternary care, which involves highly specialised treatments. While the organisation was founded by an orthopaedic surgeon, Dr Vikram Shah, and maintains a focus on orthopaedics and joint replacement surgeries, its service offerings have diversified to include multiple other specialisations. These include cardiology, neurology, oncology, critical care, and renal transplantations. Several of the company's hospitals have received accreditations that are benchmarks for quality in the Indian healthcare sector. Its hospitals in Ahmedabad (Krishna Shalby and SG Shalby), Indore, and Jabalpur are accredited by the National Accreditation Board for Hospitals & Healthcare Providers (NABH). Additionally, the Krishna Shalby and SG Shalby facilities have received accreditation from the National Accreditation Board for Testing and Calibration Laboratories (NABL) for their laboratory services.
Shalby's network includes 11 multi-speciality hospitals and four specialist Shalby Orthopaedics Centres of Excellence (SOCE), which together have more than 2,000 beds. A network of 59 outpatient clinics in 16 states in India supports this physical infrastructure. These clinics serve as places for consultations and reaching out to patients. The company has also opened outpatient clinics in Kenya, Ethiopia, Tanzania, and Uganda, among other African nations, to expand its business internationally. These clinics in other countries are the first places patients go to get help, and they also make it easier for people to go to India for medical care.
The firm has grown in stages. After building its first facility, it constructed its first big multi-speciality hospital, SG Shalby, in Ahmedabad in 2007. Things kept getting better when a hospital opened in Vapi in April 2012 and another one, Krishna Shalby, opened in Ahmedabad in October 2012. In March 2015, the firm opened a hospital in Jabalpur, Madhya Pradesh, and in August 2015, it opened another one in Indore. Shalby has used an asset-light strategy to manage and run hospitals owned by other companies, such as its agreements for facilities in Mohali and Mumbai. This is in addition to building its own facilities.
The company made an Initial Public Offer (IPO) in December 2017 to get more money. This includes new equity shares and an offer to buy shares from a current shareholder. The money was supposed to assist in paying off debts and keep the business growing. In May 2021, Shalby made a huge strategic move by buying the assets of Consensus Orthopaedics, a California-based company that develops knee and hip implants. This purchase was a move towards vertical integration, which implies that the company now controls part of its supply chain for orthopaedic implants. In April 2020, the company backed this up by creating a fully owned subsidiary called Mars Medical Devices Limited.
Shalby has been getting bigger by buying other companies in the National Capital Region (NCR) and other regions during the past few years. It obtained a majority stake in PK Healthcare Pvt Ltd, which manages Sanar International Hospital in Gurugram, in the 2024 fiscal year. This turned it into a subsidiary. After that, it purchased Healers Hospital Pvt Ltd in Gurugram. The corporation held all of it. The company has also worked on employing new medical technologies. In 2022, it established a Digital Spine Operation Room at its Ahmedabad site and began delivering Video Assisted Thoracic Surgery (VATS). It has also improved its digital infrastructure, such as by adding a centralised, cloud-based Laboratory Information System (LIS).
Who is the CEO of Shalby?
The CEO of Shalby is responsible for leading the company’s strategic vision and overseeing its healthcare operations. Under their leadership, Shalby has continued to grow and expand its presence in the healthcare industry. The CEO’s focus on enhancing service quality and operational efficiency has contributed to the company’s positive financial performance, which has had a direct influence on the Shalby share price. Investors watch the CEO’s decisions closely to assess the company’s future prospects.
When was Shalby established?
Shalby was established several decades ago, entering the healthcare sector with a focus on providing quality medical services. Since its inception, the company has grown steadily, contributing to the rise in the Shalby share price. Over the years, Shalby has expanded its hospital network and diversified its service offerings, becoming a recognised name in the healthcare industry. The company’s establishment laid the foundation for its current success and continued market presence.
What factors influence the Shalby share price?
Several factors influence the Shalby share price, including the company’s financial performance, patient admissions, and operational efficiency. Internal factors such as revenue growth, profitability, and service expansion also play a critical role. External factors like industry trends, healthcare demand, and government policies further impact the share price. Investors carefully monitor these variables to assess potential movements in the Shalby share price and make informed decisions based on market and company performance.
Is Shalby debt free?
Shalby is not entirely debt-free but maintains a manageable level of debt that supports its growth and expansion plans. The company’s financial reports reflect that its debt levels are well-controlled and do not pose significant risks to its operations. This prudent debt management strategy positively impacts investor confidence and the Shalby share price, as the company continues to maintain financial stability while pursuing growth opportunities in the healthcare sector.
How has the Shalby share price performed over the past year?
The Shalby share price has experienced moderate fluctuations over the past year, influenced by the company’s financial performance and broader market conditions. While the share price saw periods of growth driven by strong earnings and hospital expansions, it also faced some volatility due to external factors. Overall, the Shalby share price has remained stable, reflecting the company’s solid position in the healthcare industry. Investors continue to monitor the company’s performance closely for future growth potential.
Shalby Limited was originally incorporated as a Private Limited Company with the name 'Shalby Hospital Private Limited' on August 30, 2004. Subsequently, the Company was converted to a Public Limited Company and the name was changed to 'Shalby Hospital Public Limited' on May 15, 2006. Further, the name of the Company was changed to Shalby Hospitals Limited on July 26, 2006 and then, again changed to Shalby Limited on February 13, 2008.
Shalby Limited is an Ahmedabad-headquartered and one of the leading multi-specialty chain of hospitals in India and provides high-quality and economical healthcare services. With 15 hospitals and over 2,300 beds across 12 cities, Shalby is now the largest corporate hospital group in Western and Central India. The Hospitals are tertiary care hospitals, few of which offer quaternary healthcare services to patients in various areas of specialisation such as orthopaedics, complex joint replacements, cardiology, neurology, oncology, and renal transplantations.
Led by Dr. Vikram Shah, an orthopaedic surgeon, the Hospital has grown from a single hospital to a chain of multi-specialty hospitals. Apart from orthopaedics, the hospitals provide advanced levels of care across various specialties such as neurology, cardiac care, critical care, oncology, and nephrology. The Hospitals, Krishna Shalby, SG Shalby, Shalby Indore and Shalby Jabalpur are accredited by the NABH. Further, Krishna Shalby and SG Shalby are also accredited by the NABL.
The Hospital currently runs a pan-Indian chain of 11 multispecialty tertiary hospitals and 4 Single specialty Hospitals (SOCE) across 6 states with a total bed capacity of more than 2,000. Shalby has 59 outpatient clinics (OPDs) across 16 states. It also expanded global presence by opening OPDs in Kenya, Nairobi, Ethiopia, Tanzania, and Uganda in the African continent.
In 2007, the Company established operations of its first multi-specialty hospital, SG Shalby, at Sarkhej Gandhinagar Highway in Ahmedabad.
The company commenced a new hospital Shalby Vapi at Vapi in April 2012 and thereafter it commenced a new hospital Krishna Shalby in Ahmedabad in October 2012.
The company commenced a new hospital Shalby Jabalpur at Jabalpur in Madhya Pradesh in March 2015. The company commenced a new hospital Shalby Indore at Indore in August 2015.
In 2016, the company executed a memorandum of understanding with ZH Private Limited to manage and operate Zynova Shalby. During the year under review, the company executed an O&M agreement with Kamesh Hospital to commence operations of Shalby Mohali.
In 2017, the company entered into an agreement with Bait Al Batterjee Medical Company LLC, Dubai, to provide outpatient orthopaedics and spine surgeries.
The Company came up with an Initial Public Offer of 20,354,838 Equity Shares by raising capital from public aggregating to Rs 504. 8 Crores comprising a Fresh Issue of 19,354,838 Equity Shares amounting to Rs 480 Crores and an Offer for Sale of 1,000,000 Equity Shares amounting to Rs 24.8 Crore in December, 2017.
With the increase in demand of digital transformation in healthcare sector, Shalby embarked its journey of digital transformation across its all hospitals from 2018-19. In 2020, the Company launched Video Assisted Thoracic Surgery (VATS) to reduce the incidence of surgical complications. The Liver Transplant Facility became fully operational at Shalby, Ahmedabad and Mohali.
The Company incorporated a new wholly owned subsidiary Company under the name and style Mars Medical Devices Limited' on April 3, 2020. The Company also incorporated wholly-owned subsidiary company under the name and style Shalby Hospitals Mumbai Pvt. Ltd.' on December 10, 2020. In May 2021, the Company acquired the assets of Consensus Orthopaedics, a hip and knee implant manufacturing company with its facility at El Dorado Hills, USA. The Company also commenced multi-speciality rehabilitation centre at one of its Unit in 2021.
The Company launched a state-of-the-art Digital Spine Operation Room' at SG Shalby Hospital, Ahmedabad in 2022. In September 2021, the Company launched its first Shalby Orthopedics Centre of Excellence (SOCE) in the country at Udaipur. Centralised cloud based Laboratory Information System (LIS) was launched in 2022. The Company further incorporated Shalby Advanced Technologies Inc. (SAT) in the first quarter of Fiscal 2022.
In 2022-23, the Company launched a new product line of Uni Knee System called as Tahoe Unicompartmental Knee System or TUKS.
It acquired 87.26% stake in PK Healthcare Pvt Ltd (Sanar International Hospital-130 beds) in FY 2024, making it a subsidiary of the Company and further acquired 100% stake in Healers Hospital Pvt Ltd at Gurugram costing Rs 104 Crore. Company further has established new SOCE in Ranchi having 60 beds in 2024.
The new Rajkot SOCE unit became operational from July 2024. The Company opened major units at Indore and other hospitals to strengthen the super-speciality capabilities, supported by the hiring of 40 doctors focused on high-end procedures. Sanar Shalby Hospital in Gurugram, enhanced a Centre of Excellence (CoE) for liver transplants, bone marrow transplants, CT transplants and complex procedures in FY 2025.
Shalby Ltd share price is for NSE ₹ 222.22 & for BSE ₹ 222.45 as on Nov 20 2025 03:30 PM.
The market cap of Shalby Ltd for NSE ₹ 2,388.57 & for BSE ₹ 2,391.04 as on Nov 20 2025 03:30 PM.
The 52 Week High and Low of Shalby Ltd for NSE is ₹ 274.70 and ₹ 177.25 and for BSE is ₹ 274.50 and ₹ 177.20.
The 1 year returns on the stock has been 3.26%.
As on Nov 20 2025 03:30 PM the price-to-earnings (PE) ratio for Shalby Ltd share is 29.45.
As on Nov 20 2025 03:30 PM, the price-to-book (PB) ratio for Shalby Ltd share is 109.23.
You can trade in Shalby Ltd shares with Bajaj Broking by opening a demat account.
To buy Shalby Ltd shares on the Bajaj Broking app, follow these steps:
• Login to the Bajaj Broking App
• Click on the Search Icon
• Search “Shalby Ltd”
• Click on the BUY icon
• Place a buy order specifying the desired quantity of shares.
• Click BUY again to complete the purchase
No results found